Released: April 03, 2025
Expiration: October 02, 2025
Acalabrutinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2025.
Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28:2489-2495.
ASCO Post Staff. Update on withdrawal of ibrutinib accelerated approvals for MCL and MZL in the United States. https://ascopost.com/news/april-2023/update-on-withdrawal-of-ibrutinib-accelerated-approvals-for-mcl-and-mzl-in-the-united-states/ Accessed March 27, 2025
Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:18250-18255.
Ben Barouch S, Kuruvilla J, Tsang RW, et al. Radiotherapy in mantle cell lymphoma: a literature review. Hematol Oncol 2020;38:223-228.
Bond DA, Martin P, Maddocks KJ. Relapsed mantle cell lymphoma: current management, recent progress, and future directions. J Clin Med. 2021;10:1207.
Bortezomib [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2021.
Cohen JB, Shah NN, Alencar AJ, et al. MCL-133 Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk. 2022;22:S394-S395.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
Dabaja BS, Zelenetz AD, Ng AK, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28:2185-2190.
Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604-611.
Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood. 2018;132:2722-2729.
Epperla N, Switchenko JM, Geyer SM, et al. Ki-67 expression of 50% is the optimal cut-off to predict survival outcomes in mantle cell lymphoma (MCL): a pooled analysis from CALGB 50403 (Alliance) and MCL real-world study cohort. Blood. 2023;142(suppl 1):380.
Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903-1910.
Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604-1612.
Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget. 2017;8:112516-112529.
Gosney MA. Clinical assessment of elderly people with cancer. Lancet Oncol. 2005;6:790-797.
Greenwell IB, Staton AD, Lee MJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018;124:2306-2315.
Glimelius I, Smedby KE, Eloranta S, et al. Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study. Br J Haematol. 2020;189:106-116.
Halldórsdóttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011;25:1904-1908.
Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116:953-961.
Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32:1338-1346.
Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34:1386-1394.
Ibrutinib [prescribing information]. South San Francisco, CA: Pharmacyclics LLC; 2024.
Jain P, Tang G, Yin C, et al. Complex karyotype is a significant predictor for worst outcomes in patients with mantle cell lymphoma (MCL) treated with BTK inhibitors - comprehensive analysis of 396 patients. Blood. 2020a;136:32-33.
Jain P, Wang M. Blastoid mantle cell lymphoma. Hematol Oncol Clin North Am. 2020b;34:941-956.
Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638-656.
Jain P, Wang M. High-risk MCL: recognition and treatment. Blood. 2025;145:683-695.
Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109-e116.
Kumar A, Ying Z, Alperovich A, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica. 2019;104:e163-e166.
Kumar A, Eyre TA, Lewis KL, et al. New directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1-15.
Kumar A, Soumerai J, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025;145:497-507.
Lee C, Martin P. Watch and wait in mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:837-847.
Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol. 2003;14:1555-1561.
Lenalidomide [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2023.
Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatrics Soc. 1968;16:622-626.
Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209-1213.
McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63-75.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v2.2025. nccn.org. Accessed March 27, 2025.
Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. Genes (Basel). 2017;8:116.
O'Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11:720704.
Pirtobrutinib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2024.
Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104:e211-e214.
Ryan CE, Armand P, LaCasce AS. Frontline management of mantle cell lymphoma. Blood. 2025;145:663-672.
Silkenstedt E, Dreyling M. Treatment of relapsed/refractory MCL. Blood. 2025;145:673-682.
Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211-1223.
Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29-38.
Weaver JA, Peng Y, Ji Y, et al. A Medicare database analysis of practice patterns in patients with mantle cell lymphoma. J Geriatr Oncol. 2021;12:894-901.
Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:840-846.
Zanubrutinib [prescribing information]. San Mateo, CA: BeiGene USA, Inc; 2025.
Access to and use of this Interactive Decision Support Tool titled, “Interactive Treatment Decision Tool for MCL: A US Perspective” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with mantle cell lymphoma. The information provided is based on guideline recommendations and expert guidance of Stephen M. Ansell, MD, PhD; Ian Flinn, MD, PhD; Brad Kahl, MD; Tycel J. Phillips, MD; and Julie M. Vose, MD, MBA.
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC; the accredited provider; or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Interactive Treatment Decision Tool for MCL: A US Perspective” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
© 2025 Clinical Care Options, LLC. All rights reserved.